Chemotherapy of advanced dysgerminoma: Trials of the gynecologic oncology group

Stephen D. Williams, John A. Blessing, Kenneth D. Hatch, Howard D. Homesley

Research output: Contribution to journalArticlepeer-review

122 Scopus citations


Between 1984 and 1989, 20 assessable patients with incompletely resected ovarian dysgerminoma were treated on two protocols of the Gynecologic Oncology Group (GOG). All patients received cisplatin, bleomycin, and either vinblastine or etoposide. More recent patients also received consolidation chemotherapy with vincristine, dactinomycin, and cyclophosphamide (VAC). Eleven patients had clinically measurable disease, and 10 responded completely. Fourteen second-look procedures were done, and all were negative. Currently, 19 of 20 patients are disease-free with median follow-up of 26 months. Cisplatin-based chemotherapy is highly effective in patients with advanced dysgerminoma.

Original languageEnglish (US)
Pages (from-to)1950-1955
Number of pages6
JournalJournal of Clinical Oncology
Issue number11
StatePublished - Nov 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Chemotherapy of advanced dysgerminoma: Trials of the gynecologic oncology group'. Together they form a unique fingerprint.

Cite this